PregLem was acquired by Gedeon Richter in 2010 for an initial cash consideration of CHF150 million and further milestone payments of up to CHF295 million.
Gedeon Richter Plc. has announced that the European Commission has granted marketing authorisation to Esmya® 5mg tablet as pre- operative treatment of moderate to severe symptoms of uterine fibroids.
Gedeon Richter Plc. announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Esmya® as pre-operative treatment of moderate to severe symptoms of uterine fibroids.